Impact of botanical fermented foods on metabolic biomarkers and gut microbiota in adults with metabolic syndrome and type 2 diabetes: a systematic review protocol

Research output: Contribution to journalReviewResearchpeer-review

Standard

Impact of botanical fermented foods on metabolic biomarkers and gut microbiota in adults with metabolic syndrome and type 2 diabetes : a systematic review protocol. / Chan, Miin; Baxter, Helen; Larsen, Nadja; Jespersen, Lene; Ekinci, Elif I.; Howell, Kate.

In: BMJ Open, Vol. 9, No. 7, e029242, 2019.

Research output: Contribution to journalReviewResearchpeer-review

Harvard

Chan, M, Baxter, H, Larsen, N, Jespersen, L, Ekinci, EI & Howell, K 2019, 'Impact of botanical fermented foods on metabolic biomarkers and gut microbiota in adults with metabolic syndrome and type 2 diabetes: a systematic review protocol', BMJ Open, vol. 9, no. 7, e029242. https://doi.org/10.1136/bmjopen-2019-029242

APA

Chan, M., Baxter, H., Larsen, N., Jespersen, L., Ekinci, E. I., & Howell, K. (2019). Impact of botanical fermented foods on metabolic biomarkers and gut microbiota in adults with metabolic syndrome and type 2 diabetes: a systematic review protocol. BMJ Open, 9(7), [e029242]. https://doi.org/10.1136/bmjopen-2019-029242

Vancouver

Chan M, Baxter H, Larsen N, Jespersen L, Ekinci EI, Howell K. Impact of botanical fermented foods on metabolic biomarkers and gut microbiota in adults with metabolic syndrome and type 2 diabetes: a systematic review protocol. BMJ Open. 2019;9(7). e029242. https://doi.org/10.1136/bmjopen-2019-029242

Author

Chan, Miin ; Baxter, Helen ; Larsen, Nadja ; Jespersen, Lene ; Ekinci, Elif I. ; Howell, Kate. / Impact of botanical fermented foods on metabolic biomarkers and gut microbiota in adults with metabolic syndrome and type 2 diabetes : a systematic review protocol. In: BMJ Open. 2019 ; Vol. 9, No. 7.

Bibtex

@article{f1b7ae0233414b99947c520b43800d6b,
title = "Impact of botanical fermented foods on metabolic biomarkers and gut microbiota in adults with metabolic syndrome and type 2 diabetes: a systematic review protocol",
abstract = "INTRODUCTION: Dysfunctional gut microbiota is a common finding in patients with metabolic syndrome (MetS) and type 2 diabetes mellitus (T2DM). Recent clinical trials have assessed whether botanical fermented foods (BFFs) have beneficial effects on metabolic biomarkers, inflammatory markers and gut microbiota. The aim of this review is to critically evaluate all randomised controlled trials (RCTs) of BFF for evidence of impact on the outcome measures of these disease states. METHODS AND ANALYSIS: Four electronic databases (Embase, MEDLINE, CENTRAL and Google Scholar) as well as the grey literature will be searched from inception to present without language or publication status restrictions applied. Eligible RCTs which have enrolled adult participants with T2DM, any MetS components or combinations of these components, treated prophylactically or therapeutically with any botanical fermented food intervention, compared with a control group (no intervention, placebo or active control) will be assessed. Primary outcomes are related to the target conditions, including metabolic biomarkers, inflammatory markers and gut microbiota composition/function. Using Covidence, two independent investigators will conduct title and abstract screening, followed by full-text screening to identify appropriate studies. Methodological quality of the trials will be assessed using the Cochrane risk of bias assessment tool. Findings will be summarised with a narrative synthesis of the differences between included studies. A meta-analysis will be conducted if sufficient data are obtained. ETHICS AND DISSEMINATION: Ethical approval is not required as primary data will not be collected. Results will be disseminated through peer-reviewed publication, conference presentations and press. PROSPERO REGISTRATION NUMBER: CRD42018117766.",
keywords = "cardiovascular disease, clinical trial, fermented food, gut microbiota, hypertension, inflammation, metabolic syndrome, obesity, type 2 diabetes",
author = "Miin Chan and Helen Baxter and Nadja Larsen and Lene Jespersen and Ekinci, {Elif I.} and Kate Howell",
year = "2019",
doi = "10.1136/bmjopen-2019-029242",
language = "English",
volume = "9",
journal = "B M J Open",
issn = "2044-6055",
publisher = "BMJ Publishing Group",
number = "7",

}

RIS

TY - JOUR

T1 - Impact of botanical fermented foods on metabolic biomarkers and gut microbiota in adults with metabolic syndrome and type 2 diabetes

T2 - a systematic review protocol

AU - Chan, Miin

AU - Baxter, Helen

AU - Larsen, Nadja

AU - Jespersen, Lene

AU - Ekinci, Elif I.

AU - Howell, Kate

PY - 2019

Y1 - 2019

N2 - INTRODUCTION: Dysfunctional gut microbiota is a common finding in patients with metabolic syndrome (MetS) and type 2 diabetes mellitus (T2DM). Recent clinical trials have assessed whether botanical fermented foods (BFFs) have beneficial effects on metabolic biomarkers, inflammatory markers and gut microbiota. The aim of this review is to critically evaluate all randomised controlled trials (RCTs) of BFF for evidence of impact on the outcome measures of these disease states. METHODS AND ANALYSIS: Four electronic databases (Embase, MEDLINE, CENTRAL and Google Scholar) as well as the grey literature will be searched from inception to present without language or publication status restrictions applied. Eligible RCTs which have enrolled adult participants with T2DM, any MetS components or combinations of these components, treated prophylactically or therapeutically with any botanical fermented food intervention, compared with a control group (no intervention, placebo or active control) will be assessed. Primary outcomes are related to the target conditions, including metabolic biomarkers, inflammatory markers and gut microbiota composition/function. Using Covidence, two independent investigators will conduct title and abstract screening, followed by full-text screening to identify appropriate studies. Methodological quality of the trials will be assessed using the Cochrane risk of bias assessment tool. Findings will be summarised with a narrative synthesis of the differences between included studies. A meta-analysis will be conducted if sufficient data are obtained. ETHICS AND DISSEMINATION: Ethical approval is not required as primary data will not be collected. Results will be disseminated through peer-reviewed publication, conference presentations and press. PROSPERO REGISTRATION NUMBER: CRD42018117766.

AB - INTRODUCTION: Dysfunctional gut microbiota is a common finding in patients with metabolic syndrome (MetS) and type 2 diabetes mellitus (T2DM). Recent clinical trials have assessed whether botanical fermented foods (BFFs) have beneficial effects on metabolic biomarkers, inflammatory markers and gut microbiota. The aim of this review is to critically evaluate all randomised controlled trials (RCTs) of BFF for evidence of impact on the outcome measures of these disease states. METHODS AND ANALYSIS: Four electronic databases (Embase, MEDLINE, CENTRAL and Google Scholar) as well as the grey literature will be searched from inception to present without language or publication status restrictions applied. Eligible RCTs which have enrolled adult participants with T2DM, any MetS components or combinations of these components, treated prophylactically or therapeutically with any botanical fermented food intervention, compared with a control group (no intervention, placebo or active control) will be assessed. Primary outcomes are related to the target conditions, including metabolic biomarkers, inflammatory markers and gut microbiota composition/function. Using Covidence, two independent investigators will conduct title and abstract screening, followed by full-text screening to identify appropriate studies. Methodological quality of the trials will be assessed using the Cochrane risk of bias assessment tool. Findings will be summarised with a narrative synthesis of the differences between included studies. A meta-analysis will be conducted if sufficient data are obtained. ETHICS AND DISSEMINATION: Ethical approval is not required as primary data will not be collected. Results will be disseminated through peer-reviewed publication, conference presentations and press. PROSPERO REGISTRATION NUMBER: CRD42018117766.

KW - cardiovascular disease

KW - clinical trial

KW - fermented food

KW - gut microbiota

KW - hypertension

KW - inflammation

KW - metabolic syndrome

KW - obesity

KW - type 2 diabetes

U2 - 10.1136/bmjopen-2019-029242

DO - 10.1136/bmjopen-2019-029242

M3 - Review

C2 - 31366656

AN - SCOPUS:85070869650

VL - 9

JO - B M J Open

JF - B M J Open

SN - 2044-6055

IS - 7

M1 - e029242

ER -

ID: 228365259